We have developed a convenient development-scale reactor (0.44 mol/h) to prepare diazomethane fro... more We have developed a convenient development-scale reactor (0.44 mol/h) to prepare diazomethane from N-methyl-N-nitroso-p-toluenesulfonamide (MNTS) in ∼80% yield. Diazomethane (CH2N2) made with this ...
L'invention concerne des composes de mimetiques T3 contenant de l'acide phosphonique et d... more L'invention concerne des composes de mimetiques T3 contenant de l'acide phosphonique et des monoesters de ceux-ci, des stereo-isomeres, des sels pharmaceutiquement acceptables, des cocristaux et des promedicaments de ces composes, ainsi que des sels pharmaceutiquement acceptables et des cocristaux de ces promedicaments. L'invention concerne egalement leur preparation et leurs utilisations pour prevenir et/ou traiter des maladies metaboliques telles que l'obesite, la steato-hepatite non alcoolique, l'hypercholesterolemie et l'hyperlipidemie, ainsi que des troubles associes comme l'atherosclerose, la maladie coronarienne, l'intolerance au glucose, le syndrome metabolique ou syndrome X et le diabete.
L'invention concerne des compositions de composes antimicrobiens, des compositions pharmaceut... more L'invention concerne des compositions de composes antimicrobiens, des compositions pharmaceutiques, et leur utilisation et leur preparation. Dans certains modes de realisation, l'invention concerne des composes de boronate cycliques et leur utilisation en tant qu'agents therapeutiques.
In recognition of the need for effective oral therapies to treat Gram-negative bacterial infectio... more In recognition of the need for effective oral therapies to treat Gram-negative bacterial infections, efforts were directed toward identifying an oral prodrug of β-lactamase inhibitor clinical candidate QPX7728. Seventeen prodrugs were synthesized; key properties investigated were rates of cleavage to the active form in vitro, pharmacokinetics across species, and crystallinity. Compound 5-Na (QPX7831 Sodium) emerged with optimal properties across all key attributes.
The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisome... more The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.
We have developed a convenient development-scale reactor (0.44 mol/h) to prepare diazomethane fro... more We have developed a convenient development-scale reactor (0.44 mol/h) to prepare diazomethane from N-methyl-N-nitroso-p-toluenesulfonamide (MNTS) in ∼80% yield. Diazomethane (CH2N2) made with this ...
L'invention concerne des composes de mimetiques T3 contenant de l'acide phosphonique et d... more L'invention concerne des composes de mimetiques T3 contenant de l'acide phosphonique et des monoesters de ceux-ci, des stereo-isomeres, des sels pharmaceutiquement acceptables, des cocristaux et des promedicaments de ces composes, ainsi que des sels pharmaceutiquement acceptables et des cocristaux de ces promedicaments. L'invention concerne egalement leur preparation et leurs utilisations pour prevenir et/ou traiter des maladies metaboliques telles que l'obesite, la steato-hepatite non alcoolique, l'hypercholesterolemie et l'hyperlipidemie, ainsi que des troubles associes comme l'atherosclerose, la maladie coronarienne, l'intolerance au glucose, le syndrome metabolique ou syndrome X et le diabete.
L'invention concerne des compositions de composes antimicrobiens, des compositions pharmaceut... more L'invention concerne des compositions de composes antimicrobiens, des compositions pharmaceutiques, et leur utilisation et leur preparation. Dans certains modes de realisation, l'invention concerne des composes de boronate cycliques et leur utilisation en tant qu'agents therapeutiques.
In recognition of the need for effective oral therapies to treat Gram-negative bacterial infectio... more In recognition of the need for effective oral therapies to treat Gram-negative bacterial infections, efforts were directed toward identifying an oral prodrug of β-lactamase inhibitor clinical candidate QPX7728. Seventeen prodrugs were synthesized; key properties investigated were rates of cleavage to the active form in vitro, pharmacokinetics across species, and crystallinity. Compound 5-Na (QPX7831 Sodium) emerged with optimal properties across all key attributes.
The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisome... more The present invention relates to compounds of phosphonic acid containing T3 mimetics, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndromex and diabetes.
Uploads
Papers by Serge Boyer